CLLS: רווח נקי למניה (EPS TTM) Cellectis SA

Cellectis S.A. is implementing robotic TALEN systems to automate drug production. The company's environmental policy is based on energy conservation and emissions filtration. Revenues currently rely on partnership contracts while drug tests are ongoing. Net income per share over the last 12 months (TTM) reflects asset dynamics, where the current value equals -0.65, helping to identify business model risks in a timely manner.

This indicator measures the final net income allocated per common share over a rolling year, allowing for an assessment of real capital generation efficiency without the impact of equity dilution. By analyzing the 12-month rolling earnings per share history, an investor can determine the financial stability of Cellectis S.A. (CLLS) in the context of monetizing its licensing agreements and strategic alliances for the development of gene therapies.